Johnson & Johnson announced it has completed the divestiture of its Advanced Sterilization Products (ASP) business, a division of Ethicon, to Fortive for approximately $2.8 billion.
ASP had a net revenue of approximately $800 million in 2018.
ASP provides infection prevention solutions and supports health care facilities to protect patients against hospital-acquired infections. The company’s solutions include capital, consumables and software for use in low-temperature terminal sterilization and high-level disinfection of reusable surgical instruments.
News of the Fortive offer was first announced in June of last year. Johnson & Johnson said that it would discuss this transaction during its scheduled quarterly earnings call on April 16, 2019.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!